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ABSTRACT
Background The prognostic value of combination 
of C-reactive protein and prealbumin (CRP/PAlb) in 
esophageal cancer remains unclear.
Methods We enrolled 167 esophageal cancer patients 
who underwent curative esophagectomy. Univariate and 
multivariate analyses were performed to determine the 
prognostic significance of various markers, including 
CRP-to-albumin (CRP/Alb) ratio, modified Glasgow 
prognostic score, neutrophil-to-lymphocyte ratio (NLR), 
platelet-to-lymphocyte ratio (PLR), and prognostic 
nutritional index.
Results Receiver operating characteristic analysis 
revealed the optimal cut-off value of each inflammatory 
factor, and CRP/PAlb ratio had the greatest discrimina-
tive power in predicting recurrence-free survival (RFS) 
among the examined measures (AUC 0.668). The 5-year 
overall survival and RFS rates were significantly lower 
in patients with high CRP/PAlb ratio than in those with 
low CRP/PAlb ratio (P < 0.001, P = 0.001, respectively). 
In the univariate analysis, RFS was significantly worse 
in patients with low BMI, T2 or deeper tumor invasion, 
positive lymph node metastasis, positive venous inva-
sion, high CRP/PAlb ratio, high CRP/Alb ratio, high 
NLR, and high LMR. Multivariate analysis revealed 
that CRP/PAlb, but not CRP/Alb, was an independent 
prognostic factor along with lymph node metastasis.
Conclusion CRP/PAlb ratio was useful for predicting 
the prognosis of esophageal cancer patients.
Key words C-reactive protein-to-prealbumin ratio; 
esophageal cancer; esophagectomy; inf lammatory 
marker; prognosis
Esophageal cancer is the eighth most frequently diag-
nosed cancer worldwide and a highly aggressive malig-
nant disease with high metastatic potential.1 Surgery is 
the mainstay treatment for esophageal cancer, but the 
majority of patients who undergo curative resection sub-
sequently develop local or systemic recurrence. Despite 
the development of multimodal therapies, the prognosis 
of patients with esophageal cancer remains poor.2–4 
Therefore, accurate prognosis predictors are needed 
to improve patient survival and to provide appropriate 
preoperative patient counseling.
Host-related factors, such as age, performance sta-
tus, and comorbidity, as well as the biological properties 
of individual tumors, play an important role in cancer 
outcome.5 In addition to various clinicopathologic 
factors and tumor stage, other prognostic indicators for 
esophageal cancer have been identified.6–8 The close 
correlation between cancer and inflammation was first 
discovered by Virchow in 1863, and increasing evidence 
has shown that the systemic inflammatory response 
and nutritional status are associated with the long-term 
survival outcome in patients with various types of can-
cers.9–11 Therefore, a variety of inflammatory indicators, 
such as the C-reactive protein (CRP)-to-albumin ratio 
(CRP/Alb ratio), modified Glasgow prognostic score 
(mGPS), neutrophil-to-lymphocyte ratio (NLR), and 
platelet-to-lymphocyte ratio (PLR), have been explored 
as prognostic predictors in various cancers. These 
inflammatory markers have been associated with the 
prognosis of various types of cancers, including esopha-
geal cancer.12–17 However, the best predictor of long-
term outcome after potentially curative esophagectomy 
has remained unclear.
Low serum albumin concentration is another 
predictor of poor prognosis in patients with esophageal 
cancer. Several studies have shown that prealbumin has 
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a short half-life and can be used as a parameter in nutri-
tional status evaluation with demonstrated superiority to 
albumin.18–21 Prealbumin is also associated with post-
operative recovery and is an independent predictor of 
prognosis in patients with malignancies.22, 23 Recently, 
the preoperative CRP/prealbumin ratio (CRP/PAlb ratio) 
was reported to have a better predictive value for the 
recurrence of gastric cancer than traditional inflamma-
tory indices.24 However, the prognostic significance of 
CRP/PAlb ratio in esophageal cancer is unclear.
This study was performed to investigate the prog-
nostic ability of various inflammatory markers includ-




From January 2013 to December 2015, 191 consecutive 
patients with thoracic esophageal cancer underwent 
esophagectomy with radical lymph node dissection 
at the Osaka International Cancer Institute in Japan. 
Among them, 17 patients did not undergo a preoperative 
assessment of prealbumin and 7 underwent non-curative 
esophagectomy, and these 24 patients were excluded. A 
total of 167 patients were enrolled in this study. Ninety-
four patients were treated with neoadjuvant chemo-
therapy and 15 patients were treated with neoadjuvant 
chemoradiotherapy.
The treatment strategy for esophageal cancer was 
as follows: patients with ≥ T2, non-T4, or node-positive 
tumors (Stage ≥ 1B) received neoadjuvant chemo-
therapy followed by esophagectomy, and patients with 
T4 tumors suspected to have invaded other organs (T4b) 
received neoadjuvant chemoradiation therapy. Tumor 
staging was based on the 7th edition of the Union for 
International Cancer Control TNM staging system.25 
Patients were carefully followed up from the initial 
treatment until April 2019. Physical examinations and 
blood tests were performed every 3 months after dis-
charge from the hospital. Abdominal ultrasonography 
and/or computed tomography were performed at least 
every 6 months to check for recurrence. Institutional 
review board approval was obtained (No.18033), and 
informed consent requirements were waived for this 
study.
Inflammation markers
The nutrition- and inf lammation-based prognostic 
scores examined in this study were the following: 
CRP/Alb ratio (CRP measured in mg/L and albumin 
measured in g/L26); CRP/PAlb ratio (prealbumin 
measured in g/L); mGPS, which is a combination of 
CRP and albumin (patients with a normal albumin level 
(≥ 3.5 g/L) and normal CRP level (≤ 10 mg/L) were 
allocated a score of 0, patients with an elevated CRP 
level (> 10 mg/L) and a low albumin level (< 3.5 g/L) 
were allocated a score of 1, and patients with both a low 
albumin level (< 3.5 g/L) and elevated CRP level (> 10 
mg/L) were allocated a score of 227); NLR16; PLR28; 
LMR,29 and prognostic nutritional index (PNI), which 
was calculated by the formula 10 × albumin (g/dL) + 
0.005 × lymphocyte count/µL.30 All indicators involved 
in the calculation of the nutrition- and inflammation-
based prognostic scores were derived within the 5 days 
prior to surgery.
The Youden index was calculated using the 
receiver operating characteristic analysis to determine 
an optimal cutoff value for the recurrent status of 
esophageal cancer in association with each inflamma-
tory factor (CRP/Alb ratio, CRP/PAlb ratio NLR, LMR, 
PNI, and PLR).31, 32
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation. The χ2 test or Fisher’s exact test was used to 
compare categorical variables. Student’s t-test was used 
to compare continuous variables. The Mann-Whitney 
U test was used to compare sequential variables. 
The Wilcoxon test was used to compare continuous 
variables. Survival curves were calculated using the 
Kaplan-Meier method, and differences between survival 
curves were examined with the log-rank test. Cox 
regression was used for univariate and multivariate 
analyses. The hazard ratio and 95% confidence interval 
were computed with the Cox proportional hazards 
model. The recurrence-free survival (RFS) period was 
defined as the period from the date of surgery to the 
date of recurrence or last follow up without recurrence. 
For RFS, patients who died without known tumor recur-
rence were censored at the last documented evaluation. 
We used univariate and multivariate analyses of factors 
considered prognostic for RFS. All calculations were 
performed using JMP v9.0.1 (SAS Institute, Inc., Cary, 
NC), and P values of < 0.05 were considered significant.
RESULTS
Patients characteristics
The clinicopathological characteristics of patients are 
shown in Table 1. Based on the optimal cutoff, patients 
were divided into the high CRP/PAlb group (CPHigh; 
CRP/PAlb ≥ 5.517; n = 71) and low CRP/PAlb group 
(CPLow; CRP/PAlb < 5.517; n = 96). Neoadjuvant thera-
py was performed more frequently in the CPHigh group 
than in the CPLow group (P = 0.030). The CPHigh group 
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Table 1. Clinicopathologic features of patients with low or high CP
All (n = 167) CPLow (n = 96) CPHigh (n = 71) P value
Age (years) 1.000 
 < 65 67 (40.1) 39 (40.6) 28 (39.4) 
 ≥ 65 100 (59.9) 57 (59.4) 43 (60.6)
Gender 0.057 
 Male 131 (78.4) 70 (72.9) 61 (85.9)
 Female 36 (21.6) 26 (27.1) 10 (14.1)
BMI 0.756 
 < 21.0 80 (47.9) 46 (47.1) 34 (47.9)
 ≥ 21.0 87 (52.1) 50 (52.9) 37 (52.1)
Smoking 0.129 
 Present 142 (85.0) 78 (81.3) 64 (90.1)
 Absent 25 (15.0) 18 (18.7) 7 (9.9)
Tumor location, n (%) 0.355 
 Upper 35 (21.0) 21 (21.9) 14 (19.7)
 Middle 83 (49.7) 51 (53.1) 32 (45.1)
 Lower 49 (29.3) 24 (25.0) 25 (35.2)
Neoadjuvant therapy 0.030
 None 58 (34.7) 41 (42.7) 17 (23.9)
 Chemotherapy 94 (56.3) 46 (47.9) 48 (67.6)
 Chemoradiotherapy 15 (9.0) 9 (9.4) 6 (8.5)
Histology 0.172 
 Squamous cell carcinoma 159 (95.2) 94 (97.9) 65 (91.5)
 Adenocarcinoma 8 (4.8) 2 (2.1) 6 (8.5)
Lymphadenectomy 0.869 
 Two field 55 (32.9) 31 (32.3) 24 (33.8)
 Three field 112 (67.1) 65 (67.7) 47 (66.2)
Depth of tumor invasion 0.004 
 T0 24 (14.4) 15 (15.6) 9 (12.7)
 T1 58 (34.7) 44 (45.8) 14 (19.7)
 T2 21 (12.6) 10 (10.5) 11 (15.5)
 T3 62 (37.1) 26 (27.1) 36 (50.7)
 T4 2 (1.2) 1 (1.0) 1 (1.4)
Lymph node metastasis < 0.001 
 N0 75 (44.9) 56 (58.3) 19 (26.7)
 N1 58 (34.7) 26 (27.1) 32 (45.1)
 N2 19 (11.4) 9 (9.4) 10 (14.1)
 N3 15 (9.0) 5 (5.2) 10 (14.1)
Pathological stage < 0.001 
 0 12 (7.3) 7 (7.3) 5 (7.0)
 I 52 (31.1) 40 (41.7) 12 (16.9)
 II 45 (26.9) 27 (28.1) 18 (25.4)
 III 58 (34.7) 22 (22.9) 36 (50.7)
 IV 0 0 0
Data are presented as n (%). BMI, body mass index; CP, C-reactive protein-to-prealbumin ratio.
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was closely associated with poor clinical characteristics, 
including T stage (P = 0.004), N stage (P < 0.001) and 
pathological stage (P < 0.001). No correlations were 
found among age, gender, body mass index, histology 
and lymphadenectomy.
Predictive values of CRP/PAlb ratio
The Receiver operating characteristic analysis revealed 
the optimal cut-off value of each inflammatory factor 
(Table 2). CRP/PAlb ratio had the greatest discrimina-
tive power in predicting RFS among the examined 
measures (AUC 0.668). The relationships between 
CRP/PAlb ratio and various measures of the systemic 
inflammatory response in patients with esophageal 
cancer are shown in Table 3. High white blood cell 
count (P = 0.010), CRP (P < 0.001), platelet (P = 0.002) 
and CRP/Alb ratio (P < 0.001) were significantly more 
frequent in the CPHigh group than in the CPLow group. 
Low albumin (P = 0.019), prealbumin (P < 0.001) and 
PNI (P = 0.026) were significantly more frequent in 
CPHigh patients than CPLow patients. Furthermore, the 
mGPS was significantly higher in the CPHigh group 
than in the CPLow group (P < 0.001). However, there 
was no significant relationship between CRP/PAlb ratio 
and LMR, NLR and PLR. A statistically significant 
correlation was observed between CRP/PAlb ratio and 
CRP/Alb ratio (r = 0.989, P < 0.001, Fig. 1a), although 
there was only a weak correlation between prealbumin 
level and albumin level (r = 0.223, P < 0.001, Fig. 1b).
Prognosis of esophageal cancer patients
In the study group, 37 patients died of esophageal 
cancer recurrence and 6 patients died of other diseases 
(pneumonia, n = 3; other cancer, n = 2; multiple organ 
failure after a traffic accident, n =1). The overall survival 
(OS) and RFS rates were significantly poorer in CPHigh 
patients than in CPLow patients (P < 0.001 and P = 0.001, 
respectively) (Figs. 2a and b). Subgroup analyses based 
on TNM stage revealed that CRP/PAlb ratio was signifi-
cantly associated with RFS in Stage I and Stage II (Figs. 
3a–d). The OS and RFS rates were significantly poorer 
in patients with a high CRP/Alb ratio than in those with 
low CRP/Alb ratio (P < 0.001 and P = 0.007, respec-
tively) (Figs. 2c and d). Patients with higher LMR and 
NLR values had significantly poorer OS and RFS com-
pared with those with lower LMR and NLR values (Figs. 
4a–d). Patients with lower PNI values had significantly 
poorer OS compared with those with higher PNI values, 
although there was no statistical difference between PNI 
and RFS (Figs. 5a and b). However, there was no sta-
tistical difference between other inflammatory markers 
such as PLR and mGPS and prognosis of patients (Figs. 
5c and d, Figs. 6a and b).
In the univariate analysis, RFS was significantly 
worse in patients with low BMI, T2 or deeper tumor in-
vasion, positive lymph node metastasis, positive venous 
invasion, high CRP/PAlb ratio, high CRP/Alb ratio, high 
NLR and high LMR (Table 4). In multivariate analysis 
in which CRP/PAlb ratio and CRP/Alb ratio were 
included as covariates separately because a statistically 
significant correlation was observed between the two 
factors (Fig. 1a), CRP/PAlb ratio, but not CRP/Alb ratio, 
was an independent prognostic factor along with lymph 
node metastasis (Table 4).
DISCUSSION
In this study, several inf lammatory markers were 
explored as potential prognosis predictors in esophageal 
cancer. The survival rate was significantly poorer in 
patients with a high CRP/PAlb ratio, a high CRP/Alb 
ratio, high LMR and high NLR. Multivariate analysis 
revealed that only a high CRP/PAlb ratio was an inde-
pendent prognostic factor.
Our results demonstrated that CRP/PAlb ratio 
was the best prognostic factor among various systemic 
inflammation markers for esophageal cancer patients. 
Table 2. Receiver operating characteristic analysis for each inflammatory factor
Variable Cut off AUC P value
CRP/Alb ratio 0.036 0.666 0.002
CRP/PAlb ratio 5.517 0.668 0.004
LMR 3.356 0.639 0.001
NLR 3.110 0.577 0.008
PLR 172.2 0.590 0.008
PNI 42.09 0.582 0.046
AUC, area under the curve; CRP/Alb, C-reactive protein-to-albumin ratio; CRP/PAlb, C-reactive protein-to-prealbumin ratio; LMR, 
lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional 
index.
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This result is similar to that of a recent study by Jun et 
al., where the prognostic value of the CRP/PAlb ratio 
in patients with gastric cancer was explored.24 They 
retrospectively reviewed various inflammation markers 
for prognosis ability in 401 patients with gastric cancer 
and found that the predictive value of preoperative 
CRP/PAlb for the recurrence of gastric cancer was 
significantly better than other inflammatory mark-
ers. Furthermore, multivariate analysis showed that 
CRP/PAlb ratio, not CRP/Alb ratio, was an independent 
factor associated with RFS. Except for our study, there 
has been only one study showing the prognostic impact 
of the CRP/PAlb ratio in patients with esophageal 
cancer. Feng et al. retrospectively reviewed preoperative 
Table 3. The relationships between CP and various measures of the systemic inflammatory response
All (n = 167) CPLow (n = 96) CPHigh (n = 71) P value
WBC 0.010
 < 7970 149 (89.2) 91 (94.8) 58 (81.7)
 ≥ 7970 18 (10.8) 5 (5.2) 13 (18.3)
CRP < 0.001
 < 0.15 96 (57.5) 93 (96.9) 3 (4.2)
 ≥ 0.15 71 (42.5) 3 (3.1) 68 (95.8)
Albumin 0.019
 < 3.8 80 (47.9) 38 (39.6) 42 (43.8)
 ≥ 3.8 87 (52.1) 58 (60.4) 29 (56.2)
Prealbumin < 0.001
 < 24.6 74 (44.3) 28 (29.2) 46 (64.8)
 ≥ 24.6 93 (55.7) 68 (70.8) 25 (35.2)
Platelet 0.002
 < 245 80 (47.9) 56 (58.3) 24 (33.8)
 ≥ 245 87 (52.1) 40 (41.7) 47 (66.2)
CRP/Alb ratio < 0.001
 < 0.036 95 (56.9) 93 (96.9) 2 (2.8)
 ≥ 0.036 72 (43.1) 3 (3.1) 69 (97.2)
LMR 0.137
 < 3.356 112 (67.1) 69 (71.9) 43 (60.6)
 ≥ 3.356 45 (32.9) 27 (28.1) 18 (39.4)
NLR 0.570
 < 3.110 131 (78.4) 77 (80.2) 54 (76.1)
 ≥ 3.110 36 (21.6) 19 (19.8) 17 (23.9)
PLR 0.082
 < 172.2 98 (58.7) 62 (64.6) 36 (50.7)
 ≥ 172.2 69 (41.3) 34 (35.4) 35 (49.3)
PNI 0.026
 < 42.09 39 (23.4) 16 (16.7) 23 (32.4)
 ≥ 42.09 128 (76.6) 80 (83.3) 48 (67.6)
mGPS < 0.001
 0 66 (39.5) 61 (63.5) 5 (7.0)
 1, 2 101 (60.5) 35 (36.5) 66 (93.0)
CRP, C-reactive protein; CRP/Alb, C-reactive protein-to-albumin ratio; CRP/PAlb, C-reactive protein-to-prealbumin ratio; LMR, 
lymphocyte to monocyte ratio; mGPS, modified Glasgow prognostic score; NLR, neutrophil to lymphocyte ratio; PLR, platelet to 
lymphocyte ratio; pT, pathological depth of invasion; pN, pathological lymph node metastasis; PNI, prognostic nutritional index.
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Fig. 1. The correlation between each inflammatory factor. The correlation between CRP/PAlb and CRP/Alb (a) and prealbumin and 
albumin (b). CRP/Alb, C-reactive protein-to-albumin ratio; CRP/PAlb, C-reactive protein-to-prealbumin ratio.
Fig. 2. Relationship of CRP/PAlb ratio and CRP/Alb ratio with long-term prognosis. Overall (a) and recurrence-free (b) survival curves 
according to the CRP/PAlb ratio in patients with esophageal cancer. Overall (c) and recurrence-free (d) survival curves according to 
the CRP/Alb ratio in patients with esophageal cancer. CRP/Alb, C-reactive protein-to-albumin ratio; CRP/PAlb, C-reactive protein-to-
prealbumin ratio.
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CRP/PAlb ratio and CRP/Alb ratio for prognosis ability 
in 346 patients with resectable esophageal cancer and 
found that the predictive value of CRP/PAlb ratio for OS 
was better than CRP/Alb ratio. Furthermore, multivari-
ate analysis showed that CRP/PAlb ratio, not CRP/Alb 
ratio, was an independent factor associated with OS.33 
These results suggest that CRP/PAlb ratio is superior 
to CRP/Alb ratio in terms of the prognostic value of 
patients with gastric or esophageal cancer.
Elevated CRP level, which is a marker of systemic 
inf lammation, was found to be a predictor of low 
survival in patients with various cancers.34 CRP/Alb 
ratio is a superior prognostic measure involving 
inflammatory and nutritional factors in various cancers, 
including esophageal cancer.35 In our study, CRP/Alb 
ratio, CRP/PAlb ratio, LMR and NLR were suitable 
indicators of an unfavorable prognosis in patients with 
esophageal cancer, and the P values of CRP/Alb ratio 
and CRP/PAlb ratio were lower than other those of 
other inflammation markers in multivariate analyses. 
This result is similar to those of Ishibashi et al., who 
reported CRP/Alb ratio as the most significant indicator 
of poor long-term outcome in patients with esophageal 
cancer.34 The authors compared the systemic immune-
inflammatory index, NLR, PLR, and CRP/Alb ratio 
with established prognostic factors and found that the 
CRP/Alb ratio was superior to other inflammation-based 
prognostic scores in terms of prognostic ability. Wei 
et al. also retrospectively tested the mGPS, NLR, PLR 
and CRP/Alb ratio together with established prognostic 
factors in univariate and multivariate Cox regression 
analyses of OS in 423 esophageal cancer patients.36 The 
authors demonstrated that the CRP/Alb ratio showed a 
superior discriminatory ability compared with the NLR 
and PLR. These results suggest that the predictive value 
of the CRP/Alb ratio is superior to that of other inflam-
matory markers in esophageal cancer patients.
Previous studies showed that prealbumin has a 
Fig. 3. Relationship of CRP/PAlb ratio with long-term prognosis according to pathological stage. (a) Recurrence-free survival curve in 
esophageal cancer patients with Stage 0. (b) Stage I, (c) Stage II, (d) Stage III, CRP/PAlb, C-reactive protein-to-prealbumin ratio.
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shorter half-life of 2–3 days and its amount in the body 
is low.21 Therefore, measurement of prealbumin is a 
good marker of visceral protein status and prealbumin 
is affected earlier by acute variations in protein bal-
ance.37, 38 Serum albumin is commonly used as a surro-
gate marker of nutrition; however, its half-life of 21 days 
and its steady state level of 100 days limit its utility and 
value.37 Therefore, prealbumin is considered superior to 
albumin in nutritional assessment.21 Furthermore, pre-
albumin has recently been identified as an independent 
prognostic factor in various cancers.39, 40 Based on this 
theoretical advantage, CRP/PAlb may be more sensitive 
and superior to CRP/Alb for tumor prognosis. In this 
study, we found that CRP/PAlb ratio was more useful 
for predicting the prognosis of patients with esophageal 
cancer compared with CRP/Alb ratio.
Our results showed that high CRP/PAlb ratio 
was significantly associated with deeper depth of 
tumor invasion, positive lymph node metastasis and 
advanced pathological stage. This result was similar to 
the report of Jun et al. in patients with gastric cancer.24 
The authors retrospectively reviewed the association 
between CRP/PAlb and clinical features in 401 patients 
with gastric cancer and found that the CRP/PAlb ratio 
was significantly associated with deeper depth of tumor 
invasion, positive lymph node metastasis and advanced 
pathological stage. Furthermore, the CRP/PAlb ratio 
was significantly associated to inflammation markers 
including mGPS, NLR, PLR, and CRP/Alb ratio. In 
our study, CRP/PAlb ratio was significantly associated 
with mGPS, CRP/Alb ratio, and PNI. In cancer tissues, 
oncoproteins activate inflammatory transcriptional 
programs to produce various inflammatory mediators 
such as cytokines, which can trigger the proliferation 
and differentiation of inflammation markers, suggesting 
that the systemic immune inflammatory responses are 
Fig. 4. Relationship of LMR and NLR with long-term prognosis. Overall (a) and recurrence-free (b) survival curves according to the 
LMR in patients with esophageal cancer. Overall (c) and recurrence-free (d) survival curves according to the NLR in patients with 
esophageal cancer. LMR, lymphocyte -to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio.
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Fig. 5. Relationship of PLR and PNI with long-term prognosis. Overall (a) and recurrence-free (b) survival curves according to the 
PLR in patients with esophageal cancer. Overall (c) and recurrence-free (d) survival curves according to the PNI in patients with 
esophageal cancer. PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index.
Fig. 6. Relationship of mGPS with long-term prognosis. Overall (a) and recurrence-free (b) survival curves according to the mGPS in 
patients with esophageal cancer. mGPS, modified Glasgow prognostic score.
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significantly associated with tumor progression.41
This study has several limitations. First, we con-
ducted this retrospective study in a single institution, 
and the number of patients was not sufficiently large. 
Second, we included both patients with or without 
neoadjuvant therapy and we performed peripheral blood 
test only after neoadjuvant therapy. Previous studies 
showed that systemic immunoinflammatory measures 
are easily affected by chemotherapy and radiation.42 
However, Otowa et.al reported that CRP/Alb ratio after 
neoadjuvant therapy, but not CRP/Alb ratio before neo-
adjuvant therapy, was an independent prognostic factor 
in patients with Stage II/III esophageal squamous cell 
carcinoma.43 In this study, preoperative data were ob-
tained within 5 days before surgery to reduce the impact 
of preoperative treatment in patients with neoadjuvant 
chemotherapy or neoadjuvant chemoradiotherapy.
In summary, our study showed that CRP/PAlb ratio 
was superior to other systemic inflammation markers as 
a predictor of prognosis in esophageal cancer patients. 
A prospective study with a larger number of patients 
is needed to clarify the utility of CRP/PAlb ratio as a 
prognostic marker in patients with esophageal cancer.
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Table 4. Univariate and multivariate analyses of prognostic factors for recurrence-free survival in patients with 
esophageal cancer
Univariate analysis Multivariate analysis (Model A) Multivariate analysis (Model B)
Variable Hazard ratio 95% CI P value
Hazard 
ratio 95% CI P value
Hazard 
ratio 95% CI P value
Age (≥ 65 vs < 65) 1.232 0.738–2.111 0.429       
Gender (Female vs Male) 0.629 0.301–1.185 0.159       
BMI (< 21.0 vs ≥ 21.0 ) 1.694 1.025–2.839 0.040 1.592 0.939–2.697 0.084 1.637 0.965–2.775 0.067 
Smoking  
(Present vs Absent) 1.526 0.744–3.677 0.267       
Lymphatic invasion  
(Present vs Absent) 1.698 0.993–2.830 0.053 
Venous invasion  
(Present vs Absent) 2.069 1.249–3.410 0.005 1.758 0.998–3.101 0.051 1.700 0.969–2.983 0.064 
pT (2, 3, 4 vs 0, 1) 2.262 1.352–3.899 0.002 1.020 0.559–1.908 0.949 1.068 0.589–1.988 0.830 
pN (Present vs Absent) 3.931 2.197–7.564 < 0.001 2.638 1.371–5.371 0.003 2.742 1.427–5.572 0.002 
Postoperative pneumonia  
(Present vs Absent) 1.221 0.506–2.504 0.628       
Anastomosis leakage  
(Present vs Absent) 1.924 0.670–4.360 0.200 
CRP/PAlb  
(≥ 5.517 vs < 5.517) 2.234 1.352–3.740 0.002 1.771 1.037–3.067 0.036    
CRP/Alb  
(≥ 0.0360 vs < 0.0360) 1.979 1.200–3.300 0.008    1.625 0.964–2.766 0.068 
NLR (≥ 3.11 vs < 3.11) 2.066 1.197–3.461 0.010 1.377 0.743–2.502 0.304 1.316 0.712–2.385 0.375 
LMR (≥ 3.37 vs < 3.37) 2.111 1.274–3.480 0.004 1.571 0.879–2.773 0.126 1.614 0.903–2.849 0.105
PLR (≥ 172 vs < 172) 1.406 0.850–2.318 0.183       
PNI (< 42.1 vs ≥ 42.1) 1.411 0.794–2.404 0.232       
mGPS 1.640 0.970–2.878 0.065
BMI, body mass index; CI, confidence interval; CRP/Alb, C-reactive protein-to-albumin ratio; CRP/PAlb, C-reactive protein-to-
prealbumin ratio; LMR, lymphocyte to monocyte ratio; mGPS, modified Glasgow prognostic score; NLR, neutrophil to lymphocyte 
ratio; PLR, platelet to lymphocyte ratio; pT, pathological depth of invasion; pN, pathological lymph node metastasis; PNI, prognostic 
nutritional index.
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